Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear

Executive Summary

Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.


Related Content

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors
Stemline  Has What It Takes On EU Fast-Track Front  
EU Accelerated Assessment Tracker: Second Half Trumps First By Far
Pharma Q3 Results Preview: Merck Vs. Bristol In IO Showdown
ICAAC 2015: Data Help Theravance's Ongoing Vibativ Relaunch
Actavis antibiotic combo Avycaz OK'd for 2 infections
Cubist wins FDA nod for antibiotic Zerbaxa
Cubist’s Zerbaxa Approval Marks Firm’s Second Novel Antibiotic In 2014
Merck's relebactam dubbed qualified infectious disease product


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts